We as a flexible medium-sized company have the capacity to come up with novel and effective therapies for underserved patients
In Conversation
While the Paris region is the European leader in terms of patent filings, it is only in 7th place in terms of job creation. Our ambition…
The number one problem of BALT today is meeting market demands. Our products have very unique features and I truly believe they are the best on…
I must admittedly say that the generics industry is not being heard as well as we may expect by the [French] government
Here at Parexel, I have in my hands the engine of change
Overall, biologics at large are going to be the shapers of the industry moving forward, and I am glad to say our company took this path…
The research being done at Genopole puts us at the forefront of innovation
Overall, the most difficult stages of restructuring are behind us and we are moving forward with the new Teva to reach out and reengage our employees…
We manage ABL Europe as a start-up in the sense that we can be flexible and offer advantages that cannot be found in large corporations
Patient needs are evolving and natural medicine is the medicine of tomorrow
We conceive, develop, patent, manufacture, market, and distribute all of our own products – affirming Thuasne as a fully integrated group
Although we are a company with 40 years of history, we still think of ourselves in a startup mentality
